The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
May. 28, 2024

Filed:

Jan. 21, 2020
Applicant:

Hangzhou Yirui Pharmaceutical Technology Co., Ltd, Zhejiang, CN;

Inventors:

Xiaolu Wang, Zhejiang, CN;

Yongzhou Hu, Zhejiang, CN;

Qing Ye, Zhejiang, CN;

Xiuai Hu, Zhejiang, CN;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07D 295/205 (2006.01); A61P 17/06 (2006.01); C07D 207/14 (2006.01); C07D 211/46 (2006.01); C07D 211/52 (2006.01); C07D 211/54 (2006.01); C07D 211/58 (2006.01); C07D 211/74 (2006.01); C07D 211/88 (2006.01); C07D 213/42 (2006.01); C07D 231/12 (2006.01); C07D 233/36 (2006.01); C07D 233/64 (2006.01); C07D 241/08 (2006.01); C07D 277/28 (2006.01); C07D 295/155 (2006.01); C07D 307/52 (2006.01);
U.S. Cl.
CPC ...
C07D 295/205 (2013.01); A61P 17/06 (2018.01); C07D 207/14 (2013.01); C07D 211/46 (2013.01); C07D 211/52 (2013.01); C07D 211/54 (2013.01); C07D 211/58 (2013.01); C07D 211/74 (2013.01); C07D 211/88 (2013.01); C07D 213/42 (2013.01); C07D 231/12 (2013.01); C07D 233/36 (2013.01); C07D 233/64 (2013.01); C07D 241/08 (2013.01); C07D 277/28 (2013.01); C07D 295/155 (2013.01); C07D 307/52 (2013.01);
Abstract

The invention provides an N-benzyl-N-arylsulfonamide derivative, which is an N-benzyl-N-arylsulfonamide compound represented by formula (I) or a pharmaceutically acceptable salt or solvate thereof. The N-benzyl-N-arylsulfonamide derivative is obtained by condensing a substituted nitrobenzene with 5- or 6-membered nitrogen-containing aliphatic heterocycle (the ring B), reducing the nitro group to an amino group, and subjecting the amino group to reductive amination, sulfonamidation; or by subjecting a substituted nitrobenzene to nitro reduction, reductive amination and sulfonamidation, and condensing the resultant intermediate with 5- or 6-membered nitrogen-containing aliphatic heterocycle (the ring B). It has been experimentally demonstrated that the N-benzyl-N-arylsulfonamide derivative of the invention can specifically bind to Kv1.3 potassium channel and inhibit or decrease its activity, and is useful in the treatment of autoimmune diseases caused by abnormal activation of the Kv1.3 potassium channel in human or animals. The invention further provides a medicament or a pharmaceutical composition comprising the N-benzyl-N-arylsulfonamide derivative.


Find Patent Forward Citations

Loading…